Increased PCSK9 associated with cIMT in AS: A useful marker for subclinical atherosclerosis in patients with ankylosing spondylitis
| dc.authorid | 0000-0001-8288-9744 | |
| dc.authorid | 0000-0002-4367-2355 | |
| dc.authorid | 0000-0003-1711-5157 | |
| dc.authorid | 0000-0002-8519-5382 | |
| dc.authorid | 0000-0002-7173-3530 | |
| dc.authorid | 0000-0002-8044-7616 | |
| dc.authorid | 0000-0001-8028-1671 | |
| dc.contributor.author | Karakoyun, Ahmet | |
| dc.contributor.author | Akkubak, Yasemin | |
| dc.contributor.author | Göktepe, Mevlüt Hakan | |
| dc.contributor.author | Yılmaz, Pınar Diydem | |
| dc.contributor.author | Kadıyoran, Cengiz | |
| dc.contributor.author | Oğul, Mustafa | |
| dc.contributor.author | Kucuk, Adem | |
| dc.date.accessioned | 2025-02-07T13:13:23Z | |
| dc.date.available | 2025-02-07T13:13:23Z | |
| dc.date.issued | 2024 | |
| dc.department | Tıp Fakültesi | |
| dc.description.abstract | This study aims to investigate the relationship between proprotein convertase subtilisin/ kexin type 9 (PCSK9) levels and subclinical atherosclerosis (SA) in patients with ankylosing spondylitis (AS). Patients and methods: Between January 2022 and March 2022, a total of 56 patients (33 males, 23 females; mean age: 37.8±9.3 years; range, 20 to 60 years) who were under regular follow-up in our clinic and fulfilled the criteria of the Modified New York Diagnostic Criteria for AS and American College of Rheumatology (ACR) for AS were included. Age-and sex-matched 56 healthy volunteers (25 males, 31 females; mean age: 38.4±8.2 years; range, 20 to 60 years) were also recruited as the control group. Demographic, clinical, and laboratory data were recorded. The PCSK9 level and carotid intima-media thickness (cIMT) were evaluated using appropriate methods. Results: The mean serum PCSK9 levels in AS patients (609.3±149.9 vs. 136.3±120.8 ng/mL, p<0.001) and the mean cIMT values (0.51±0.19 vs. 0.43±0.08 mm, p=0.003) were higher than healthy controls. In the multivariate stepwise regression analysis, there was an independent relationship between SA and PCSK9 (?=0.324, p=0.001). Additionally, there was an independent relationship between carotid plaque and PCSK9 (?=0.265, p=0.006). Based on the receiver operating characteristic curve analysis, the optimal PCSK9 cut-off value for plaque was 472.0 ng/mL, sensitivity 90.9%, specificity 65.0% (area under the curve [AUC]=0.759; 95% CI: 0.660-0.857, p=0.005). The optimal PCSK9 cut-off value for SA was 459.5 ng/mL, sensitivity 63.2%, specificity 63.0% (AUC=0.625; 95% CI: 0.512-0.739, p=0.031). Conclusion: Our study showed that serum PCSK9 levels in patients with AS were higher than that in healthy individuals and were associated with SA and arterial plaque formation. | |
| dc.identifier.doi | 10.46497/ArchRheumatol.2024.10625 | |
| dc.identifier.endpage | 661 | en_US |
| dc.identifier.issn | 2618-6500 | |
| dc.identifier.issue | 4 | en_US |
| dc.identifier.startpage | 652 | en_US |
| dc.identifier.uri | https://dx.doi.org/10.46497/ArchRheumatol.2024.10625 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12451/12939 | |
| dc.identifier.volume | 39 | en_US |
| dc.language.iso | en | |
| dc.publisher | Turkish League Against Rheumatism (TLAR) | |
| dc.relation.ispartof | Archives of Rheumatology | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Ankylosing Spondylitis | |
| dc.subject | Carotid Intima-media Thickness | |
| dc.subject | Proprotein Convertase Subtilisin/kexin type 9 | |
| dc.subject | Subclinical Atherosclerosis | |
| dc.title | Increased PCSK9 associated with cIMT in AS: A useful marker for subclinical atherosclerosis in patients with ankylosing spondylitis | |
| dc.type | Article |
